Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

MORU’s Medicine Quality Research Group (MQRG) organised a multidisciplinary hybrid meeting at Keble College, Oxford, 3-6 July for the Wellcome Collaborative Award-funded FORESFA project (‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’).

FORESFA conference 2022 Oxford group photo

The multidisciplinary hybrid meeting drew 53 colleagues from 12 countries, including pharmacists, forensic geneticists and chemists, modellers, sociologists, data scientists, informaticians, microbiologists, criminologists, public engagement specialists and food safety scientists, with national and international organization representatives. They met for vibrant discussions and planning for FORESFA. Those present in person went for after lunch walks, including to the Sir William Dunn School of Pathology blue plaque commemorating where penicillin was first brewed up to administer to patients (pictured).

On 6-8 July, the indefatigable MQRG held another, overlapping, multidisciplinary hybrid meeting, also at Keble, to discuss the Vaccine Identity Evaluation (VIE) project, which is evaluating devices for screening for substandard and falsified (SF) vaccines in supply chains. The VIE team, of the CTMGH, Department of Biochemistry and Department of Chemistry, Oxford and the Science and Technology Facilities Council’s Rutherford Appleton Laboratory (RAL), were joined by 60 colleagues from 11 countries including vaccine and device manufacturers, medicines regulators, virologists, chemists, physicists, forensic scientists, data scientists, police and investigators, sociologists and translational research experts. Pilot data were discussed and much progress made on future collaborative plans with a vision to bring about a step change in our ability to detect SF vaccines. The diverse devices were demonstrated at RAL and in Biochemistry and Chemistry.

- Paul Newton.

Similar stories

Landmark DeTACT project holds final Investigators’ meeting

On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.